Table 3 Change in scores across treatment and follow-up period (mean ± SE)
From: Escitalopram in the prevention of posttraumatic stress disorder: a pilot randomized controlled trial
Start (week 2) to end (week 24) of treatment | End of treatment (week 24) to 6 month follow-up (week 56) | |||
|---|---|---|---|---|
Escitalopram | Placebo | Escitalopram | Placebo | |
CAPS | −29.29 (±4.76)** | −44.11 (±3.81)** | −5.85 (±6.98) | −7.69 (±4.22) |
CGI-S | −1.41 (±0.20)** | −1.50 (±0.16)** | −0.36 (±0.22) | −0.18 (±0.17) |
CGI-I | −1.60 (±0.70) | −1.75 (±1. 70) | −1.00 (±0.00) | −1.42 (±0.52) |
MADRS | −8.62 (±1.94)** | −11.99 (±1.55)** | −1.59 (±2.24) | −1.10 (±1.72) |
VAS-D | −2.17 (±0.61)** | −2.89 (±0.49)** | −0.57 (±0.70) | −0.18 (±0. 45) |
VAS-A | −2.81 (±0.72)** | −2.63 (±0.54)** | −0.32 (±0.77) | −1.01 (±0.60) |
SDS | −5.58 (±1.58)** | −8.25 (±1.26)** | −1.96 (±1.82) | −1.16 (±1.40) |